Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8–20) Data from a Real-World Multicenter Retrospective Review
Restricted accessLetterFirst published online May, 2025
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8–20) Data from a Real-World Multicenter Retrospective Review
Guttman-YasskyE, TeixeiraHD, SimpsonEL, et al.Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure up 1 and Measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet., 2021; 397(10290):2151–2168.
2.
ReichK, TeixeiraHD, de Bruin-WellerM, et al.Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet., 2021; 397(10290):2169–2181.
3.
Guttman-YasskyE, ThaçiD, PanganAL, et al.Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020; 145(3):877–884.
4.
PezzoloE, OrtoncelliM, FerrucciSM, et al.Drug survival of upadacitinib and predicting factors of discontinuation in adult patients affected by moderate-to-severe atopic dermatitis: An Italian multicenter analysis. J Clin Med. 2024; 13(2):553; doi: 10.3390/jcm13020553 Published 2024 Jan 18.
5.
ChiricozziA, OrtoncelliM, SchenaD, et al.Correction to: Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: An interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023; 24(6):963–964; doi: 10.1007/s40257-023-00813-4
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
